Pyxis Oncology (NASDAQ:PYXS) Rating Lowered to “Sell” at Wall Street Zen

Pyxis Oncology (NASDAQ:PYXS) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Sunday.

PYXS has been the subject of a number of other research reports. Zacks Research lowered Pyxis Oncology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a report on Thursday. Guggenheim lifted their price target on Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Royal Bank Of Canada cut their price objective on shares of Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a research report on Thursday, December 18th. Finally, HC Wainwright lifted their target price on shares of Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.20.

Pyxis Oncology Price Performance

Shares of NASDAQ PYXS opened at $1.61 on Friday. Pyxis Oncology has a one year low of $0.83 and a one year high of $5.55. The firm’s 50 day simple moving average is $2.81 and its two-hundred day simple moving average is $2.44. The stock has a market capitalization of $100.24 million, a P/E ratio of -1.01 and a beta of 1.44.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.01. As a group, equities analysts expect that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pyxis Oncology

A number of institutional investors and hedge funds have recently modified their holdings of PYXS. Bank of America Corp DE grew its holdings in shares of Pyxis Oncology by 20.3% in the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock worth $84,000 after acquiring an additional 9,062 shares during the period. Acadian Asset Management LLC purchased a new position in Pyxis Oncology in the first quarter worth about $81,000. Schulhoff & Co. Inc. boosted its position in Pyxis Oncology by 125.4% in the second quarter. Schulhoff & Co. Inc. now owns 275,000 shares of the company’s stock worth $302,000 after purchasing an additional 153,000 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of Pyxis Oncology during the 2nd quarter valued at about $146,000. Finally, Catalyst Funds Management Pty Ltd purchased a new stake in shares of Pyxis Oncology during the 2nd quarter valued at about $26,000. 39.09% of the stock is currently owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.